Early use of convalescent plasma may help outpatients with covid-19 avoid hospitalization

Findings from Johns Hopkins–led study support antibody-rich blood as an early treatment option The results of a nationwide, multicenter clinical trial led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health provide solid evidence for the use of plasma from convalescent patients—those who have recovered from the disease and whose […]

Read More

FDA Allows COVID Convalescent Plasma for Some Outpatients

The FDA on Tuesday both limited and expanded the emergency use authorization (EUA) for convalescent plasma as a treatment for COVID-19. In its updated EUA, the agency restricted the use of high-titer COVID-19 convalescent plasma to immunocompromised patients, but stated that “these patients may be treated in outpatient or inpatient settings.” (Previously, use […]

Read More